The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
Beth A. Hellerstedt
Research Funding - Exelixis
Gerald Edelman
Research Funding - Exelixis
Nicholas J. Vogelzang
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis
Harriet M. Kluger
Research Funding - Exelixis
Christopher A. Yasenchak
Research Funding - Exelixis
Xiaodong Shen
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
David A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Michael S. Gordon
Research Funding - Exelixis
Primo Lara
Research Funding - Exelixis